1. Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
- Author
-
Gregory P. Geba, Ruifeng Chen, Kasturi Talapatra, Taylor Brackin, Kusha A. Mohammadi, Robert Pordy, Garen Manvelian, David J. Maron, Gregory G. Schwartz, Michael Szarek, Ph. Gabriel Steg, and Sergio Fazio
- Subjects
Acute coronary syndrome ,Alirocumab ,Cardiovascular disease ,Chest pain ,Proprotein convertase subtilisin/kexin type 9 ,Low-density lipoprotein cholesterol ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Public aspects of medicine ,RA1-1270 - Abstract
Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS. This post hoc analysis of ODYSSEY OUTCOMES assessed the effect of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, on the incidence of chest pain not due to recurrent ACS. Methods: Patients with recent ACS (n = 18,894) and elevated atherogenic lipoprotein levels despite optimized statin therapy were randomized to subcutaneous alirocumab or matching placebo every 2 weeks. Alirocumab dose was adjusted to target low-density lipoprotein cholesterol (LDL-C) 25–50 mg/dL (0.6–1.3 mmol/L) and to avoid consecutive LDL-C
- Published
- 2024
- Full Text
- View/download PDF